Results 51 to 60 of about 1,848 (184)

Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients

Pulmonary Circulation, 2021
There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients.
Nael Aldweib, Nathan J. Verlinden, Hayah Kassis‐George, Amresh Raina   +3 more
doaj   +1 more source

Pulmonary Arterial Hypertension Associated With Chronic Mephedrone Use: A Case Report

Pulmonary Circulation, Volume 16, Issue 4, October 2026.
ABSTRACT Mephedrone is a synthetic cathinone with sympathomimetic effects, but has not previously been linked to pulmonary arterial hypertension (PAH). We report a 42‐year‐old woman with no prior cardiopulmonary disease who presented with severe pre‐capillary PAH after a decade of near‐daily mephedrone use.
Masoud Kashoub, Michael Plunkett, Heba Nashat, Konstantinos Dimopoulos, Colm McCabe, Carl Harries, S. John Wort, Paul I. Dargan, Laura C. Price   +8 more
wiley   +1 more source

Right Ventricular Function Improves With Pulmonary Vasodilator Treatment in Pediatric Patients With Pulmonary Hypertension and Multivessel Pulmonary Vein Stenosis in a Single Center Cohort

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Pulmonary hypertension (PH) and right ventricular (RV) dysfunction increase mortality in multivessel pediatric pulmonary vein stenosis (PVS). Pulmonary vasodilator use is limited in PVS due to the perceived risk of pulmonary edema. We aimed to describe our experience with pulmonary vasodilators in PVS and to assess changes in RV function and ...
Catherine M. Avitabile, Kimberly Butler, Antara Mondal, David B. Frank, Yan Wang, Devon Ash, Laura Mercer‐Rosa, Michael L. O'Byrne, Ryan Callahan   +8 more
wiley   +1 more source

Clinical Practice of Pulmonary Arterial Hypertension (PAH) and Potential Barriers to Intensive Treatment Among PAH‐Specialized and Non‐PAH‐Specialized Centers in Japan

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by remodeling of the pulmonary vasculature, which leads to increased pulmonary artery pressure and ultimately right ventricular failure. Although Japanese guidelines recommend combination therapy, real‐world data show inconsistencies in its implementation. We
Yoko Arai, Wen Zhang, Shohei Yamauchi, Shigeru Tokita, Shunta Akutsu   +4 more
wiley   +1 more source

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration [PDF]

, 2023
This corrects the article Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration ...
Morales-Demori, Raysa, Rozmeen Fombin, Elise Whalen, Ruiz, Fadel E, Ely, Erin, Ryan D. Coleman, Erin Ely, Fombin, Rozmeen, Raysa Morales-Demori, Nidhy P. Varghese, Faircloth, Jenna M, Neelam D. Bhatt, Corey A. Chartan, Chartan, Corey A, Coleman, Ryan D, Villafranco, Natalie, Fadel E. Ruiz, Bhatt, Neelam D, Natalie Villafranco, Jenna M. Faircloth, Whalen, Elise, Varghese, Nidhy P   +21 more
core   +1 more source

Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag

Journal of Patient-Reported Outcomes, 2023
Background Understanding patients’ perspectives regarding drug tolerability, in addition to effectiveness, provides a complete picture of the patient experience and supports more informed therapeutic decision-making.
Stacy Davis, Teresa Edwards, Lindsey Norcross, Sheri Fehnel, Amélie Beaudet, Marie Eckart, John Fastenau   +6 more
doaj   +1 more source

Preliminary Clinical and Laser Speckle Contrast Analysis Data on Selexipag Efficacy for the Treatment of Digital Vasculopathy in Systemic Sclerosis

, 2023
Objective. Systemic sclerosis (SSc) is burdened by Raynaud phenomenon (RP) and digital ulcers (DUs), and sometimes standard vasoactive therapies are ineffective or contraindicated.
De Mattia G., Rio M. D., Mosca M., Morganti R., Battista M. D., Rossa A. D.   +5 more
core   +1 more source

SELEXIPAG CRYSTALLINE FORM [PDF]

Considerations relating to crystalline form 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl) amino]butoxy}-N(methylsulfonyl) acetamide (Selexipag) are set out ...

core   +1 more source

Phenotypic Clustering of Idiopathic Pulmonary Arterial Hypertension: Insights Into Pulmonary Vascular and Cardiometabolic Co‐Morbidity Trajectories

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Idiopathic pulmonary arterial hypertension (IPAH) exhibits significant clinical heterogeneity, necessitating a precision medicine approach. This study aimed to identify distinct IPAH phenotypes using machine learning‐based clustering and to evaluate their longitudinal therapeutic responses and long‐term survival.
Cihangir Kaymaz, Barkin Kultursay, Hacer Ceren Tokgoz, Seda Tanyeri, Cagdas Bulus, Berhan Keskin, Caglar Emre Cagliyan, Metehan Kibar, Can Erdem, Aziz Vezir, Ipek Akkus, Muhammet Bulut, Aykun Hakgor, Ibrahim Halil Tanboga, Nihal Ozdemir   +14 more
wiley   +1 more source

Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis

Journal of Health Economics and Outcomes Research, 2022
# Background Agents targeting the prostacyclin (PGI~2~) pathway are important in managing pulmonary arterial hypertension (PAH). No head-to-head clinical trials have compared outcomes between the 3 different PGI~2~-pathway drugs most commonly available ...
Ci Song, Peter Kunovszki, Amélie Beaudet   +2 more
doaj   +1 more source